Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin Lymphoma

Copy of Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin LymphomaПодробнее

Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin LymphomaПодробнее

Results of ECHELON-1 study for Hodgkin LymphomaПодробнее

ECHELON-1 Trial: Significance in Hodgkin LymphomaПодробнее

Dr. Hutchings on the Aim of the ECHELON-1 Study in Hodgkin LymphomaПодробнее

Radhakrishnan Ramchandren, MD, elaborates on the five-year follow-up data from ECHELON-1Подробнее

Research Builds On Positive ECHELON-1 Study in Hodgkin LymphomaПодробнее

Updates from the ECHELON-1 studyПодробнее

A 10-year PFS simulation model based on the ECHELON-1 trial in Hodgkin lymphomaПодробнее

Dr. Hutchings on Subgroup Analysis of ECHELON-1 in Hodgkin LymphomaПодробнее

Updated 3-Year Findings of ECHELON-1 Trial Presented for Classical Hodgkin LymphomaПодробнее

Five year update of ECHELON-1 for classical Hodgkin lymphomaПодробнее

Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHLПодробнее

Overview of ECHELON-1 Study for Hodgkin LymphomaПодробнее

Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin LymphomaПодробнее

An analysis of older patients treated with brentuximab vedotin in the ECHELON-1 trialПодробнее

Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022Подробнее

Dr. Kaplan on the Phase III ECHELON-1 Trial in Hodgkin LymphomaПодробнее

5-Year Update of the ECHELON-1 StudyПодробнее